Radioprotection of hematopoietic progenitors by low dose amifostine prophylaxis

References

• Benjamin GC, McGeary M, McCutchen SR. 2009. Assessing medical preparedness to respond to a terrorist nuclear event: Workshop report. Washington, DC: The National Academies Press.
   Google Scholar
• Blankenbecler R. 2010. Low-dose pretreatment for radiation therapy. Dose Response 8:534–542.
   PubMed Web of Science ®Google Scholar
• Brechignac F, Paquet F. 2013. Radiation-induced risks at low dose: Moving beyond controversy towards a new vision. Radiat Environ Biophys 52:299–301.
   PubMed Web of Science ®Google Scholar
• Brown DQ, Graham WJ 3rd, MacKenzie LJ, Pittock JW 3rd, Shaw LM. 1988. Can WR-2721 be improved upon?Pharmacol Therapeut 39:157–168.
   PubMed Web of Science ®Google Scholar
• Calabrese EJ. 2001. Overcompensation stimulation: A mechanism for hormetic effects. Crit Rev Toxicol 31:425–470.
   PubMed Web of Science ®Google Scholar
• Capizzi RL. 1999. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol 26:3–21.
   PubMed Web of Science ®Google Scholar
• Capizzi RL, Oster W. 2000. Chemoprotective and radioprotective effects of amifostine: An update of clinical trials. Int J Hematol 72:425–435.
   PubMed Web of Science ®Google Scholar
• Carter RE, Verrllei DM. 1973. AFRRI cobalt whole-body irradiation. Technical Note 73-3. Bethesda, MD: Armed Forces Radiobiology Research Institute.
   Google Scholar
• Coleman CN, Blakely WF, Fike JR, MacVittie TJ, Metting NF, Mitchell JB, Moulder JE, Preston RJ, Seed TM, Stone HB, Tofilon PJ, Wong RS. 2003. Molecular and cellular biology of moderate-dose (1–10 Gy) radiation and potential mechanisms of radiation protection: Report of a workshop at Bethesda, Maryland, December 17–18, 2001. Radiat Res 159:812–834.
   PubMedGoogle Scholar
• Cortdy M. 1995. Murine colony assay (BFU-E, CFU-GM, CFU-GEMM). Stem cell technologies, Vancouver, BC, Canada.
   Google Scholar
• Davidson DE, Grenan MM, Sweeney TR. 1980. Biological characteristics of some improved radioprotectors. In: Brady LW, editor. Radiation sensitizers. Their use in the clinical management of cancer. New York: Masson.
   Google Scholar
• Day TK, Zeng G, Hooker AM, Bhat M, Turner DR, Sykes PJ. 2007. Extremely low doses of X-radiation can induce adaptive responses in mouse prostate. Dose Response 5:315–322.
   PubMedGoogle Scholar
• Dorr RT. 1998. Radioprotectants: Pharmacology and clinical applications of amifostine. Semin Radiat Oncol 8:10–13.
   PubMed Web of Science ®Google Scholar
• Fatome M, Courteille F, Laval JD, Roman V. 1987. Radioprotective activity of ethylcellulose microspheres containing WR 2721, after oral administration. Int J Radiat Biol Rel Stud Phys, Chem Med 52:21–29.
   PubMed Web of Science ®Google Scholar
• Ferguson CD, Potter WC, Sands A, Spector LS, Wehling FL. 2004. The four faces of nuclear terrorism. Monterey, CA: Center for Nonproliferation Studies, Monterey Institute of International Studies Nuclear Threat Initiative.
   Google Scholar
• Giambrarresi LI, Walker RI. 1989. Prospects of radioprotection. In: Office of the Surgeon General, DOTA, USA. Medical Consequences of Nuclear Warfare. Falls Church, VA: TMM Publications.
   Google Scholar
• Grdina DJ, Murley JS, Kataoka Y, Epperly W. 2002. Relationships between cytoprotection and mutation prevention by WR-1065. Milit Med 167:51–53.
   PubMedGoogle Scholar
• Greenberger JS. 2008. Gene therapy approaches for stem cell protection. Gene Ther 15:100–108.
   PubMed Web of Science ®Google Scholar
• Held KD, Awad S. 1991. Effects of polyamines and thiols on the radiation sensitivity of bacterial transforming DNA. Int J Radiat Biol 59:699–710.
   PubMed Web of Science ®Google Scholar
• Institute of Laboratory Animal Resources – Commission on Life Sciences, NRC. 1996. Guide for the care and use of laboratory animals. Washington, DC: National Academy Press.
   Google Scholar
• Khodarev NN, Kataoka Y, Murley JS, Weichselbaum RR, Grdina DJ. 2004. Interaction of amifostine and ionizing radiation on transcriptional patterns of apoptotic genes expressed in human microvascular endothelial cells (HMEC). Int J Radiat Oncol, Biol, Phys 60:553–563.
   PubMed Web of Science ®Google Scholar
• Landauer MR, Davis HD, Dominitz JA, Weiss JF. 1987. Dose and time relationships of the radioprotector WR-2721 on locomotor activity in mice. Pharmacol, Biochem Behav 27:573–576.
   PubMed Web of Science ®Google Scholar
• Landauer MR, Davis HD, Dominitz JA, Weiss JF. 1988a. Comparative behavioral toxicity of four sulfhydryl radioprotective compounds in mice: WR-2721, cysteamine, diethyldithiocarbamate, and N-acetylcysteine. Pharmacol Therapeut 39:97–100.
   PubMed Web of Science ®Google Scholar
• Landauer MR, Davis HD, Dominitz JA, Weiss JF. 1988b. Long-term effects of radioprotector WR-2721 on locomotor activity and body weight of mice following exposure to ionizing radiation. Toxicology 49:315–323.
   PubMed Web of Science ®Google Scholar
• Landauer MR, Davis HD, Kumar KS, Weiss JF. 1992. Behavioral toxicity of selected radioprotectors. Adv Space Res 12:273–283.
   PubMedGoogle Scholar
• Lechpammer S, Epperly MW, Zhou S, Nie S, Glowacki J, Greenberger JS. 2005. Adipocyte differentiation in Sod2(+/+) and Sod2(+/+) murine bone marrow stromal cells is associated with low antioxidant pools. Experim Hematol 33:1201–1208.
   PubMed Web of Science ®Google Scholar
• Ledney GD, Elliott TB, Harding RA, Jackson WE 3rd, Inal CE, Landauer MR. 2000. WR-151327 increases resistance to Klebsiella pneumoniae infection in mixed-field- and gamma-photon-irradiated mice. Int J Radiat Biol 76:261–271.
   PubMed Web of Science ®Google Scholar
• Mazur L. 1996. Effects of sulphur-containing compounds and X-rays on the mouse erythropoietic system assayed by in-vivo peripheral blood micronucleus test. Strahlenther Onkol 172:25–29.
   PubMedGoogle Scholar
• Meijne EI, Ploemacher RE, Huiskamp R. 1996. Sensitivity of murine haemopoietic stem cell populations to X-rays and 1 MeV fission neutrons in vitro and in vivo under hypoxic conditions. Int J Radiat Biol 70:571–577.
   PubMed Web of Science ®Google Scholar
• Meijne EI, van der Winden-van Groenewegen RJ, Ploemacher RE, Vos O, David JA, Huiskamp R. 1991. The effects of x-irradiation on hematopoietic stem cell compartments in the mouse. Exp Hematol 19:617–623.
   PubMed Web of Science ®Google Scholar
• Mitchel RE. 2006. Low doses of radiation are protective in vitro and in vivo: Evolutionary origins. Dose Response 4:75–90.
   PubMedGoogle Scholar
• Murley JS, Constantinou A, Kamath NS, Grdina DJ. 1997. WR-1065, an active metabolite of the cytoprotector amifostine, affects phosphorylation of topoisomerase II alpha leading to changes in enzyme activity and cell cycle progression in CHO AA8 cells. Cell Proliferat 30:283–294.
   PubMed Web of Science ®Google Scholar
• Myska JC, Adams TL, Bhatt RC, Broom JG, Pitcher CD, Sharpnack FM, St John TJ, Torres BA, Vavrina G, Gerstenberg HM. 1997. Arrays for use at the cobalt irradiation facility. Technical Report97-2. Bethesda, M D: Armed Forces Radiobiology Research Institute.
   Google Scholar
• North S, El-Ghissassi F, Pluquet O, Verhaegh G, Hainaut P. 2000. The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway. Oncogene 19:1206–1214.
   PubMed Web of Science ®Google Scholar
• Orlic D, Fischer R, Nishikawa S, Nienhuis AW, Bodine DM. 1993. Purification and characterization of heterogeneous pluripotent hematopoietic stem cell populations expressing high levels of c-kit receptor. Blood 82:762–770.
   PubMed Web of Science ®Google Scholar
• Pamujula S, Graves RA, Freeman T, Srinivasan V, Bostanian LA, Kishore V, Mandal TK. 2004. Oral delivery of spray dried PLGA/amifostine nanoparticles. J Pharmacy Pharmacol 56:1119–1125.
   PubMed Web of Science ®Google Scholar
• Pamujula S, Kishore V, Rider B, Fermin CD, Graves RA, Agrawal KC, Mandal TK. 2005. Radioprotection in mice following oral delivery of amifostine nanoparticles. Int J Radiat Biol 81:251–257.
   PubMed Web of Science ®Google Scholar
• Patchen ML, D’Alesandro MM, Chirigos MA, Weiss JF. 1988. Radioprotection by biological response modifiers alone and in combination with WR-2721. Pharmacol Therapeut 39:247–254.
   PubMed Web of Science ®Google Scholar
• Patchen ML, MacVittie TJ. 1994. Granulocyte colony-stimulating factor and amifostine (Ethyol) synergize to enhance hemopoietic reconstitution and increase survival in irradiated animals. Semin Oncol 21:26–32.
   PubMed Web of Science ®Google Scholar
• Patchen ML, MacVittie TJ, Weiss JF. 1990. Combined modality radioprotection: The use of glucan and selenium with WR-2721. Int J Radiat Oncol, Biol, Phys 18:1069–1075.
   PubMed Web of Science ®Google Scholar
• Pellmar TC, Rockwell S. 2005. Priority list of research areas for radiological nuclear threat countermeasures. Radiat Res 163: 115–123.
   PubMedGoogle Scholar
• Piper JR, Stringfellow CR Jr, Elliott RD, Johnston TP. 1969. S-2-(omega-aminoalkylamino)ethyl dihydrogen phosphorothioates and related compounds as potential antiradiation agents. J Medicinal Chem 12:236–243.
   PubMed Web of Science ®Google Scholar
• Ploemacher RE, van Os R, van Beurden CA, Down JD. 1992. Murine haemopoietic stem cells with long-term engraftment and marrow repopulating ability are more resistant to gamma-radiation than are spleen colony forming cells. Int J Radiat Biol 61:489–499.
   PubMed Web of Science ®Google Scholar
• Purdie JW, Inhaber ER, Schneider H, Labelle JL. 1983. Interaction of cultured mammalian cells with WR-2721 and its thiol, WR-1065: Implications for mechanisms of radioprotection. Int J Radiat Biol Rel Stud Phys, Chem Med 43:517–527.
   PubMed Web of Science ®Google Scholar
• Ramdas J, Warrier RP, Scher C, Larussa V. 2003. Effects of amifostine on clonogenic mesenchymal progenitors and hematopoietic progenitors exposed to radiation. J Pediatric Hematol/Oncol 25:19–26.
   PubMed Web of Science ®Google Scholar
• Seed T, Kumar S, Whitnall M, Srinivasan V, Singh V, Elliott T, Landauer M, Miller A, Chang CM, Inal C, Deen J, Gehlhaus M, Jackson W 3rd, Hilyard E, Pendergrass J, Toles R, Villa V, Miner V, Stewart M, Benjack J, Danilenko D, Farrell C. 2002a. New strategies for the prevention of radiation injury: Possible implications for countering radiation hazards of long-term space travel. J Radiat Res 43(Suppl.):S239–244.
   Google Scholar
• Seed TM. 2005. Radiation protectants: Current status and future prospects. Health Phys 89:531–545.
   PubMed Web of Science ®Google Scholar
• Seed TM, Fry SA, Neta R, Weiss JF, Jarrett DG, Thomassen D. 2002b. Prevention and treatments: Summary statement. Milit Med 167:87–93.
   PubMedGoogle Scholar
• Singh VK, Seed TM. 2003. Radiation effects. In: Roy MJ, editor. Physician's guide to terrorist attack. Totowa, NJ: Humana Press.
   Google Scholar
• Srinivasan V, Pendergrass JA Jr, Kumar KS, Landauer MR, Seed TM. 2002. Radioprotection, pharmacokinetic and behavioural studies in mouse implanted with biodegradable drug (amifostine) pellets. Int J Radiat Biol 78:535–543.
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Weiss JF, Kumar KS. 1992. Radioprotection by combinations of WR-151327, vitamin E and selenomethionine. Proc 40th Annual Meeting of the Radiation Research Society.
   Google Scholar
• Stone HB, Moulder JE, Coleman CN, Ang KK, Anscher MS, Barcellos-Hoff MH, Dynan WS, Fike JR, Grdina DJ, et al. 2004. Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3–4, 2003. Radiat Res 162:711–728.
   Google Scholar
• Turrisi AT, Glover DJ, Hurwitz S, Glick J, Norfleet AL, Weiler C, Yuhas JM, Kligerman MM. 1986. Final report of the phase I trial of single-dose WR-2721 [S-2-(3-aminopropylamino)ethylphosphorothioic acid]. Cancer Treat Rep 70:1389–1393.
   PubMedGoogle Scholar
• Walker RI. 1988. Requirements of radioprotectors for military and emergency needs. Pharmacol Therapeut 39:13–20.
   PubMed Web of Science ®Google Scholar
• Weiss JF. 1997. Pharmacologic approaches to protection against radiation-induced lethality and other damage. Environ Health Perspect 105(Suppl. 6):1473–1478.
   PubMed Web of Science ®Google Scholar
• Weiss JF, Srinivasan V, Kumar KS, Landauer MR. 1992. Radioprotection by metals: Selenium. Adv Space Res 12:223–231.
   PubMedGoogle Scholar
• Whitnall MH, Wilhelmsen CL, McKinney L, Miner V, Seed TM, Jackson WE 3rd. 2002. Radioprotective efficacy and acute toxicity of 5-androstenediol after subcutaneous or oral administration in mice. Immunopharmacol Immunotoxicol 24:595–626.
   PubMed Web of Science ®Google Scholar